Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Inclusion Criteria: * 18 years of age or over. * At least one suspected soft tissue sarcoma tumor that is considered by the investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm in shortest dimension for patients undergoing an excisional biopsy/tumor resection. Tumors should not be selected if the Investigator believes them to be necrotic or exhibit signs of radiation-induced fibrosis. * Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor being injected. * ECOG performance status of 0-2 (or a Karnofsky performance status of \>50%) * Labs required for enrollment (prior to microinjection): * Absolute neutrophil count \> 1000/mm3 * Platelet count \> 50,000/mm3 * Hematocrit \> 25% * Creatinine \<3.0 mg/dl * Total Bilirubin \<4.0 mg/dl * Bilirubin \<4.0 mg/dl, SGOT ≤ 1.5 times the upper limit of normal * PT and PTT ≤ 1.5 times the upper limit of normal Exclusion Criteria: * Subjects with active fungal, viral, or bacterial infections. * Pregnant women. * Inability to give informed consent. * Current treatment with anticoagulation such as warfarin or low-molecular-weight heparin. * Tumors near critical structures such as those located near or in the brain or spine. This assessment will be determined by the treating clinician.